Trials / Completed
CompletedNCT04604496
STUDY OF PF-06882961 IN PARTICIPANTS WITH AND WITHOUT VARYING DEGREES OF HEPATIC IMPAIREMENT
A Phase 1, Non-randomized, Open-label, Single-dose, Parallel Cohort Study to Compare the Pharmacokinetics of PF-06882961 in Adult Participants With Varying Degrees of Hepatic Impairment Relative to Participants Without Hepatic Impairment.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
The current study is proposed to evaluate whether there is any clinically meaningful effect of hepatic impairment on the plasma Pharmacokinetic (PK) of PF-06882961
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PF-06882961 20MG | PF-06882961 in 20 mg oral tablet will be administered on Day 1 |
Timeline
- Start date
- 2020-12-30
- Primary completion
- 2022-01-10
- Completion
- 2022-01-10
- First posted
- 2020-10-27
- Last updated
- 2024-03-21
- Results posted
- 2024-03-21
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04604496. Inclusion in this directory is not an endorsement.